Coherent Market Insights

Small Molecule Injectable Drugs Market to Surpass US$ 347.0 Bn by 2030

Small Molecule Injectable Drugs Market to Surpass US$ 347.0 Bn by 2030 - Coherent Market Insights

Publish In: Jun 06, 2022

Global Small Molecule Injectable Drugs Market, by Drug Class (Chemotherapy, Small Molecule Antibiotics, Skeletal Muscle Relaxants, Analgesics, Anticoagulants, Anticonvulsants, Antivirals, and Others), by Indication (Oncology, Pain Management, Cardiovascular Diseases, Infectious Diseases, CNS Diseases, and Others), by Mode of Delivery (IV Set, Infusion Pump, Intravenous Injection, Intramuscular Injection, and Subcutaneous Injection), by End User (Hospitals, Ambulatory Clinics, Outpatient Facility, Infusion Therapy Center, Home Care, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 188.9 billion in 2022 and is expected to exhibit a CAGR of 7.9% during the forecast period (2022-2030).

Market players are involved in receiving product approvals from the regulatory authorities, in order to expand their product portfolio. This is expected to drive growth of the global small molecule injectable drugs market over the forecast period. For instance, in June 2021, Cipla Limited, a pharmaceutical company and its subsidiary Cipla USA, Inc., announced that the company received approval for its Lanreotide injection from the U.S. Food and Drug Administration (U.S. FDA). Lanreotide injection will be supplied in 90 mg/0.3 mL, 60 mg/0.2 mL, and 120 mg/0.5 mL single dose pre-filled syringes. This injection is indicated for the treatment of patients with gastroenteropancreatic neuroendocrine tumors and acromegaly.

Market players are engaged in research and development activities for development of new small molecule injectable drugs. This is expected to drive growth of the global small molecule injectable drugs market, over the forecast period. For instance, in 2019, GlaxoSmithKline plc., a pharmaceutical company, announced that patient dosing has commenced in a phase III clinical trial investigating gepotidacin, the first of a novel chemical class of antibiotics known as triazaacenaphthylene bacterial topoisomerase inhibitors, in patients with uncomplicated urinary tract infection (UTI) also known as acute cystitis and urogenital gonorrhoea (GC).

Global Small Molecule Injectable Drugs Market- Impact of Coronavirus (COVID – 19) Pandemic

The coronavirus disease (COVID-19) pandemic is expected to drive growth of the global small molecule injectable drugs market over the forecast period. COVID-19 is the recent pandemic outbreak, which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO) Weekly epidemiological update on COVID-19, the number of new cases are decreasing after May 15, 2022. Therefore, as of May 15, 2022, around 518 million cases and over 6 million deaths have been reported.

Non-profit organizations across the world are investing for development of small molecule drugs for the treatment of COVID-19, this is expected to increase the growth of the market, over the forecast period. For instance, COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of US$ 8.4 million from the Wellcome Trust, on behalf of the Covid-19 Therapeutics Accelerator.

Browse 37 Market Data Tables and 45 Figures spread through 408 Pages and in-depth TOC on Global Small Molecule Injectable Drugs Market, by Drug Class (Chemotherapy, Small Molecule Antibiotics, Skeletal Muscle Relaxants, Analgesics, Anticoagulants, Anticonvulsants, Antivirals, and Others), by Indication (Oncology, Pain Management, Cardiovascular Diseases, Infectious Diseases, CNS Diseases, and Others), by Mode of Delivery (IV Set, Infusion Pump, Intravenous Injection, Intramuscular Injection, and Subcutaneous Injection), by End User (Hospitals, Ambulatory Clinics, Outpatient Facility, Infusion Therapy Center, Home Care, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the small molecule injectable drugs market, click the link below:

https://www.coherentmarketinsights.com/market-insight/small-molecule-injectable-drugs-market-5033

Market players are engaged in inorganic activities such as collaborations, in order to expand their product portfolio. This is expected to drive growth of the global small molecule injectable drugs market, over the forecast period. For instance, in November 2021, Philogen S.p.A., a clinical-stage biotechnology company, announced that Philochem AG, its wholly-owned Switzerland-based  subsidiary, entered into a new collaboration and option agreement with Janssen Biotech, Inc., one of Johnson & Johnson's Janssen Pharmaceutical Companies to discover new small molecules using Philochem's novel lead-generation technologies.

Key Takeaways of the Small Molecule Injectable Drugs Market:

  • The global small molecule injectable drugs market is expected to exhibit a CAGR of 7.9% over the forecast period (2022-2030), owing to growth in potential markets, especially in Europe. While North America accounted for the major market share.
  • Market players are engaged in signing agreements with other manufacturers, in order to expand their product portfolio as well as increase customer base. This is expected to drive growth of the global small molecule injectable drugs market, over the forecast period. For instance, in October 2020, Hikma Pharmaceuticals and Arecor Limited, a biopharmaceutical company, announced a new exclusive agreement to co-develop a ready-to-administer injectable medicine in the U.S. through Hikma's subsidiary, Hikma Pharmaceuticals USA Inc.
  • Major players operating in the global small molecule injectable drugs market include Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd. AstraZeneca Plc, Baxter International Inc., Fresenius Kabi AG, Cipla Limited., Mylan N.V., GlaxoSmithKline Plc., Johnson & Johnson, Sanofi S.A., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG (Genentech, Inc.), Amgen, Inc., Gilead Sciences, Inc., and Hikma Pharmaceuticals plc

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports


Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail


Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Created billion dollars of revenue impact on thousands of clients

trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.